Rapamycin (sirolimus)
mTOR inhibitor being studied for effects on aging biology and healthspan-related outcomes.
Where the science stands
This page summarizes the current human evidence captured in the Longevity Compass database. Result interpretation is conservative and unresolved outcomes remain unknown.
Research path
From biological idea to human evidence
These stages show different kinds of evidence for Rapamycin (sirolimus). Moving through them does not mean an intervention is proven to slow aging.
- 1
Biological idea
Reviewing animal and laboratory research…
- 2
Human testing
8 direct aging trial links and 10 related trial links tracked. A trial count describes research activity, not benefit.
- 3
What results show
0 beneficial, 0 neutral and 0 harmful result links interpreted; 11 remain unresolved.
- 4
Still unanswered
Whether these findings translate into meaningful, lasting healthy-aging benefits in people remains unproven. Longer follow-up and clearer safety and clinical outcomes are needed.
Beyond human trials
The bigger longevity story
Loading animal and laboratory evidence…
Animal and cell studies help explain biological plausibility and identify promising directions. They are shown separately and do not increase the human evidence-depth score.
Signals we're watching
What human studies are measuring
Living longer
4 result(s) are linked, but direction remains unknown.
Research depth
Human evidence picture
Evidence depth describes how much relevant human research exists; it is not an efficacy score. Unknown results are not treated as neutral.
Interpreted results
- Beneficial
- 0
- Neutral
- 0
- Harmful
- 0
- Unknown / unresolved
- 11
Population relevance
- Healthy / aging
- 0
- Disease-specific
- 1
Safety evidence
Trials currently identified with safety-result data.
Go to the source
Studies & publications
Inspect the original evidence behind this profile. Links open the trial registry, PubMed or the publication DOI.
The big unanswered question
Can promising biology translate into meaningful healthy-aging benefits?
That is the standard this evidence profile is tracking. New trials and results can strengthen, weaken or change the picture over time.